The Analysis of Risk Factors for Recurrent Pregnancy Loss and Prediction of Pregnancy Loss Risk

Launched by RENJI HOSPITAL · Feb 7, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the factors that may contribute to repeated pregnancy loss, which is when a woman has two or more miscarriages before 28 weeks of pregnancy. Researchers will look at the medical history and test results of women who have experienced recurrent miscarriages to identify what may increase their risk of losing a pregnancy again. The goal is to create a prediction tool that helps doctors identify women at higher risk and provide them with early interventions and treatments to improve their chances of having a successful pregnancy.

To participate in this trial, women must be at least 20 years old and have a diagnosis of recurrent miscarriage. They should have experienced two or more losses with the same partner and have completed specific medical tests. Women who are currently pregnant, have serious health issues that make pregnancy unsafe, or who choose to withdraw from the study will not be eligible. Participants can expect to undergo a thorough evaluation and provide informed consent, meaning they understand the study and agree to take part. The trial aims to better understand and support women facing the challenges of recurrent pregnancy loss.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of recurrent miscarriage: patients who had two or more spontaneous miscarriages (including biochemical pregnancies, excluding spontaneous miscarriages due to chromosomal abnormalities in the embryo) before 28 weeks of gestation with the same partner prior to the consultation were included in this study;
• • 2. ≥20 years old;
• • 3. Completion of initial history taking and complete results of the etiological screening programme;
• • 4. Knowledge of the purpose and significance of the study, consent and sign the informed consent form;
• Exclusion Criteria:
• • 1. Pregnant at the first visit;
• • 2. Presence of severe contraindications to pregnancy, making it inadvisable to conceive;
• • 3. Voluntary withdrawal from the pregnancy or from the study;
• • 4. No pregnancy outcome as of the follow-up endpoint (December 31, 2023), indicating no pregnancy;
• • 5. Loss to follow-up, unable to obtain pregnancy outcome;
• • 6. Subsequent pregnancy outcomes after the clinic visit included ectopic pregnancy, molar pregnancy, fetal malformations, and pregnancy at the scar site of previous cesarean section.